Eli Lilly’s Strategic Surge Meets Market Skepticism

Eli Lilly & Co. is executing a multi-billion dollar expansion on two critical fronts, yet its stock performance tells a different story. Shares have declined roughly 12% since the start of the year, pressured by pricing dynamics and political headwinds, even as the company launches a groundbreaking new drug and seals a major acquisition.

The pharmaceutical giant received U.S. FDA approval for its oral GLP-1 pill, Foundayo, positioning it directly against Novo Nordisk’s recently launched Wegovy pill. Analysts highlight a key practical advantage: Foundayo can be taken without food or fluid restrictions. CEO Dave Ricks confirmed the company is gearing up for a global rollout, with plans to secure approvals in over 40 countries this year. To ensure broad access, Lilly has set a price point starting at $25 per month for patients with private insurance and $149 for cash payers, with a potential $50 monthly cost for Medicare beneficiaries starting in July. The scale of Lilly’s commitment is underscored by its pre-approval inventory build-up, valued at $1.5 billion.

All eyes are now on the company’s first-quarter 2026 earnings report, scheduled for April 30. Wall Street will scrutinize the initial sales figures for Foundayo. Analysts view any revenue approaching $500 million for the partial first quarter as a strong indicator that the market for oral GLP-1 drugs is expanding faster than anticipated.

Simultaneously, Lilly is making a massive bet on neuroscience with its planned acquisition of Centessa Pharmaceuticals. The deal carries an upfront cost of $6.3 billion, or $38 per share, representing a premium of approximately 41% to Centessa’s 30-day average price. Potential milestone payments could add another $1.5 billion, contingent on meeting certain FDA approval deadlines. The transaction is expected to close in the third quarter of 2026.

Should investors sell immediately? Or is it worth buying Eli Lilly?

The strategic prize is Centessa’s lead candidate, cleminorexton, an OX2R agonist that has shown promise in Phase 2a studies for narcolepsy and idiopathic hypersomnia. Lilly also sees potential for the drug in broader neurological conditions like Alzheimer’s and depression. The move is a clear bid to bolster its smallest division, which generated about $1.4 billion in revenue in 2025. RBC Capital Markets analyst Brian Abrahams described the sleep-disorder market as “virtually commercial and billion-dollar,” a segment missing from Lilly’s current portfolio. The company faces competitive pressure, however, as Takeda’s rival candidate, oveporexton, is already under FDA priority review and could launch by late 2026.

This aggressive expansion is unfolding against a challenging backdrop. Lilly is navigating price reductions for its weight-loss injection Zepbound, a slowdown in revenue growth, and the near-term earnings impact of the Centessa deal. Politically, the company has publicly opposed potential pharmaceutical import tariffs, warning they would raise costs and limit patient access.

Despite these pressures, analyst sentiment remains largely positive. Guggenheim recently adjusted its price target slightly downward from $1,168 to $1,163 but maintained a Buy rating. Overall, 16 out of 19 Wall Street analysts recommend purchasing the stock. Lilly’s own full-year guidance projects revenue between $80 and $83 billion and earnings per share of $33.50 to $35.00. The upcoming quarterly report will be the first concrete test of whether the company’s costly strategic bets are beginning to pay off.